Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTHMEI)

Drug Name
INS 316 Drug Info
Synonyms
Uridine 5'-triphosphate; uridine 5'-triphosphate; uridine triphosphate; 63-39-8; Uteplex; UTP; Uridine 5'-(tetrahydrogen triphosphate); 5'-UTP; Uridine 5'-triphosphoric acid; H4utp; UNII-UT0S826Z60; BRN 0071520; INS316; EINECS 200-558-7; uridine-5'-triphosphate; CHEMBL336296; CHEBI:15713; UT0S826Z60; Uridine5'-(tetrahydrogen triphosphate); [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate; uridine5'-triphosphate; uridintriphosphat; uridine tetrahydrogen
Indication
Disease Entry ICD 11 Status REF
Lung cancer 2C25.0 Discontinued in Phase 3 [1]
Cross-matching ID
PubChem CID
6133
ChEBI ID
CHEBI:15713
CAS Number
CAS 63-39-8
TTD Drug ID
DMTHMEI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Investigative Drug(s)
Clinical Trial Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting P2Y purinoceptor 4 (P2RY4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PPADS DMWHN3T Discovery agent N.A. Investigative [8]
UTPgammaS DMKLB4O Discovery agent N.A. Investigative [9]
CTP DM4T62U Discovery agent N.A. Investigative [4]
ITP DMVFITX Discovery agent N.A. Investigative [4]
2-amino-uridine-5'-monophosphate DMO792L Discovery agent N.A. Investigative [10]
MRS2927 DMB2A7Q Discovery agent N.A. Investigative [11]
MRS4062 DMWKXGP Discovery agent N.A. Investigative [11]
N4-phenylethoxycytidine-5'-triphosphate DM7KX2V Discovery agent N.A. Investigative [11]
(N)methanocarba-UTP DM6SV7I Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Targeting P2Y purinoceptor 6 (P2RY6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GC021109 DMQBEYV Alzheimer disease 8A20 Phase 1 [13]
adenosine diphosphate DMFUHKP N. A. N. A. Investigative [5]
2MeSATP DMUE0W6 Discovery agent N.A. Investigative [5]
RB 2 DMCEFUW Discovery agent N.A. Investigative [14]
PSB-0952 DMW19LB Discovery agent N.A. Investigative [14]
5BrUTP DMEVRH4 Discovery agent N.A. Investigative [5]
MRS2782 DMZSO4R Discovery agent N.A. Investigative [15]
MRS2578 DMKMPS6 Discovery agent N.A. Investigative [16]
UDP-beta-S DMMWHAV Discovery agent N.A. Investigative [17]
Up3U DMKQWSB Discovery agent N.A. Investigative [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting P2Y purinoceptor 11 (P2RY11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2MeSATP DMUE0W6 Discovery agent N.A. Investigative [18]
BzATP DM37GYA Discovery agent N.A. Investigative [18]
ATPgammaS DMXHQIN Discovery agent N.A. Investigative [18]
NAADP DM51DW6 Discovery agent N.A. Investigative [19]
NF546 DMPZB31 Discovery agent N.A. Investigative [20]
dATP DMMXFBJ Discovery agent N.A. Investigative [18]
NF157 DMGMH8T Discovery agent N.A. Investigative [21]
NF340 DMPSXR8 Discovery agent N.A. Investigative [22]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Targeting P2Y purinoceptor 2 (P2RY2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Diquafosol DM64QG9 Dry eye disease 9E1Z Phase 3 [23]
INS-37217 DMF93RQ Cystic fibrosis CA25 Phase 2 [23]
PSB-0963 DMBDVJ1 Discovery agent N.A. Investigative [14]
RB 2 DMCEFUW Discovery agent N.A. Investigative [24]
UTPgammaS DMKLB4O Discovery agent N.A. Investigative [25]
Acid blue 25 DMCU6XV Discovery agent N.A. Investigative [14]
5BrUTP DMEVRH4 Discovery agent N.A. Investigative [25]
2-thioUTP DMJZ5V0 Discovery agent N.A. Investigative [26]
SB-416 DMJW72O Discovery agent N.A. Investigative [24]
MDT-006 DMSF4UI Constipation DD91.1 Investigative [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-6 (IL6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [28]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [29]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [30]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [31]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [32]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [33]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [34]
Imiquimod DM1TMA3 Alopecia areata ED70.2 Approved [35]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [36]
Methotrexate DM2TEOL Anterior urethra cancer Approved [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [37]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [38]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [39]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [40]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [41]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [42]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [43]
Gefitinib DM15F0X Colon adenocarcinoma Approved [44]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [45]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ethanol DMDRQZU Chronic pain MG30 Approved [47]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [38]
Carvedilol DMHTEAO Chronic heart failure BD1Z Approved [48]
Paclitaxel DMLB81S Breast carcinoma Approved [49]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [50]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [37]
Urokinase DM0GOUD Myocardial infarction BA41-BA43 Approved [51]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [52]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [40]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [41]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P2Y purinoceptor 11 (P2RY11) TTYXPCO P2Y11_HUMAN Agonist [2]
P2Y purinoceptor 2 (P2RY2) TTOZHQC P2RY2_HUMAN Modulator [3]
P2Y purinoceptor 4 (P2RY4) TT24DGP P2RY4_HUMAN Agonist [4]
P2Y purinoceptor 6 (P2RY6) TTNVSKA P2RY6_HUMAN Agonist [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Gene/Protein Processing [6]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Post-Translational Modifications [7]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Post-Translational Modifications [7]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008257)
2 Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling. Mol Pharmacol. 2003 Jun;63(6):1356-63.
3 Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol. 2001 Aug;32(2):122-8.
4 ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. Mol Pharmacol. 2000 May;57(5):926-31.
5 Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8.
6 Involvement of P2Y11 receptor in silica nanoparticles 30-induced IL-6 production by human keratinocytes. Toxicology. 2014 Aug 1;322:61-8. doi: 10.1016/j.tox.2014.03.010. Epub 2014 May 2.
7 Cellular injury induces activation of MAPK via P2Y receptors. J Cell Biochem. 2004 Apr 1;91(5):938-50. doi: 10.1002/jcb.10774.
8 Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal. 2009 Mar;5(1):75-89.
9 Enzymatic synthesis of UTP gamma S, a potent hydrolysis resistant agonist of P2U-purinoceptors. Br J Pharmacol. 1996 Jan;117(1):203-9.
10 Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2011 Apr 28;54(8):2878-90.
11 Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate delta-ester modifications as selective agonists of the P2Y(4) receptor. J Med Chem. 2011 Jun 23;54(12):4018-33.
12 Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem. 2002 Jan 3;45(1):208-18.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
15 Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem. 2008 Jun 15;16(12):6319-32.
16 Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol. 2004 May 1;67(9):1763-70.
17 P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312.
18 Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
19 NAADP+ is an agonist of the human P2Y11 purinergic receptor. Cell Calcium. 2008 Apr;43(4):344-55.
20 NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Ther. 2010 Jan;332(1):238-47.
21 Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J Med Chem. 2005 Nov 3;48(22):7040-8.
22 Invited Lectures : Overviews Purinergic signalling: past, present and future. Purinergic Signal. 2006 May;2(1):1-324.
23 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
24 Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 1;18(1):223-7.
25 Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol. 1995 Sep;116(1):1619-27.
26 Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2006 Nov 30;49(24):7076-87.
27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 324).
28 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
29 Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. Eur J Cancer. 2010 Jul;46(10):1848-55. doi: 10.1016/j.ejca.2010.03.026. Epub 2010 Apr 17.
30 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
31 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
32 Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
33 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
34 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
35 (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
36 Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
37 Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
38 Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
39 Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
40 Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
41 Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
42 Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
43 Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
44 Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
45 Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
46 SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
47 Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
48 A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
49 The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
50 Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
51 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
52 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.